Result of AGM

By

Regulatory News | 11 Jul, 2024

Updated : 11:06

RNS Number : 0617W
Dr. Martens PLC
11 July 2024
 

11 July 2024

DR. MARTENS PLC

RESULT OF ANNUAL GENERAL MEETING

11 JULY 2024

 

The Company announces the results of voting at its Annual General Meeting held earlier today and confirms that all resolutions were duly passed on a poll with majorities as set out below.

Resolutions 1 to 16 were proposed as Ordinary Resolutions and resolutions 17 to 20 as Special Resolutions.

Resolution

 

 

 

Votes
For

(note 1)

 

%

 

 

Votes Against

(note 1)

 

%

 

 

Votes
Total

 

 

Votes Withheld

(note 2)

% Voting

Capital Instructed

01

Receive the 2024 Annual Report and Accounts

789,653,948

99.87%

1,016,107

0.13%

790,670,055

389,119

82.18

02

Approve the Directors' Remuneration Report

784,551,256

99.18%

6,479,754

0.82%

791,031,010

28,164

82.22

03

Approve the Remuneration Policy

784,540,438

99.18%

6,484,634

0.82%

791,025,072

34,102

82.22

04

Approve the Final Dividend

790,899,254

99.98%

138,398

0.02%

791,037,652

21,522

82.22

05

Elect Giles Wilson

790,575,687

99.94%

472,252

0.06%

791,047,939

11,235

82.22

06

Re-elect Paul Mason

739,380,746

98.45%

11,649,105

1.55%

751,029,851

40,029,322

78.06

07

Re-elect Kenny Wilson

782,546,350

99.38%

4,857,639

0.62%

787,403,989

3,655,185

81.84

08

Re-elect Andrew Harrison

784,035,245

99.11%

7,011,325

0.89%

791,046,586

12,587

82.22

09

Re-elect Ian Rogers

784,033,188

99.11%

7,013,122

0.89%

791,046,586

12,587

82.22

10

Re-elect Lynne Weedall

782,969,980

98.98%

8,079,606

1.02%

791,049,586

9,587

82.22

11

Re-elect Robyn Perriss

783,169,527

99.00%

7,880,059

1.00%

791,049,586

9,587

82.22

12

Re-elect Tara Alhadeff

775,890,657

98.53%

11,583,929

1.47%

787,474,586

3,584,587

81.85

13

Re-appoint PricewaterhouseCoopers LLP as auditor

790,431,574

99.92%

619,491

0.08%

791,051,065

8,109

82.22

14

Authorise the Audit & Risk Committee to determine the Auditor's remuneration

790,886,095

99.98%

160,465

0.02%

791,046,560

12,614

82.22

15

Authorise the Company and its subsidiaries to make political donations

782,418,912

99.36%

5,046,388

0.64%

787,465,300

3,593,874

81.85

16

Authorise allotment of shares

781,095,005

99.30%

5,488,607

0.70%

786,583,612

4,475,562

81.76

17

Authorise general disapplication of pre-emption rights*

744,775,869

94.58%

42,685,045

5.42%

787,460,914

3,598,260

81.85

 18

Authorise additional disapplication of pre-emption rights*

743,752,064

94.45%

43,708,850

5.55%

787,460,914

3,598,260

81.85

19

Authorise purchase of own shares*

772,052,557

97.61%

18,934,341

2.39%

790,986,898

72,276

82.22

20

Authorise calling of general meetings on 14 days' notice*

788,373,014

99.66%

2,680,102

0.34%

791,053,116

6,058

82.22

*Special Resolution

 

The votes of independent shareholders on the resolutions concerning the election or re-election of the Independent Non-Executive Directors are set out below:

Resolution

 

 

Votes
For

 

%

 

Votes Against

 

%

 

Votes
Total

 

Votes Withheld

 

% Independent

Capital Instructed

08

Re-elect Andrew Harrison

414,092,821

98.34%

7,011,325

1.66%

421,104,146

12,587

71.12%

09

Re-elect Ian Rogers

414,091,024

98.33%

7,013,122

1.67%

421,104,146

12,587

71.12%

10

Re-elect Lynne Weedall

413,027,540

98.08%

8,079,606

1.92%

421,107,146

9,587

71.13%

11

Re-elect Robyn Perriss

413,227,087

98.13%

7,880,059

1.87%

421,107,146

9,587

71.13%

 

Notes:

1.     Votes "For" and "Against" are expressed as a percentage of votes received.

2.    A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

3.    As at 6.30pm on 9 July 2024 the Company had a total of 962,080,090 ordinary shares with voting rights in issue. The total independent voting capital, used to calculate the votes of independent shareholders on resolutions 8 to 11, was 592,062,882.

4.     In accordance with Listing Rule 9.6.2R, copies of the resolutions passed as special business will shortly be available for inspection on the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.  

 

Enquiries

Company Secretariat

Paul Rolling, Assistant Company Secretary                                                                   +44 7584 243562

 

Investors and analysts                                                                     

Bethany Barnes, Director of Investor Relations                                                             +44 7825 187465

                                                                                                                                        bethany.barnes@drmartens.com

Media                                                                                                                                                  

Gill Hammond, Director of Communications                                                                +44 7384 214248

 

H/Advisors Maitland                                                                                                      +44 20 7379 5151

Katharine Spence                                                                                                            +44 7384 535739                               

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGGPUCUMUPCGUG

Last news